CAPTOR THERAPEUTICS SPOLKA AKCYJNA Financials Captor Therapeutics Spolka Akcyjna
Equities
CTX
PLCPTRT00014
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 79.8 PLN | -0.25% |
|
-0.50% | -19.39% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 742.2 | 666.9 | 370.7 | 370.7 | - |
| Enterprise Value (EV) 1 | 632.4 | 583 | 308.2 | 327.9 | 319.5 |
| P/E ratio | - | - | - | - | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 186 x | 72.8 x | 18.3 x | 7.06 x | 4.72 x |
| EV / Revenue | 159 x | 63.7 x | 15.2 x | 6.25 x | 4.07 x |
| EV / EBITDA | -26 x | -18.6 x | -4.24 x | -20.5 x | 23.7 x |
| EV / FCF | -18.8 x | -24.5 x | -4 x | -6.31 x | -13.3 x |
| FCF Yield | -5.31% | -4.09% | -25% | -15.9% | -7.51% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 4,128 | 4,168 | 4,646 | 4,646 | - |
| Reference price 2 | 179.8 | 160.0 | 79.80 | 79.80 | 79.80 |
| Announcement Date | 4/29/22 | 4/6/23 | - | - | - |
1PLN in Million2PLN
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | 3.986 | 9.158 | 20.3 | 52.5 | 78.5 |
| EBITDA 1 | -24.35 | -31.27 | -72.75 | -16 | 13.5 |
| EBIT 1 | -31.71 | -38.36 | -78.85 | -23.5 | 5 |
| Operating Margin | -795.51% | -418.91% | -388.42% | -44.76% | 6.37% |
| Earnings before Tax (EBT) 1 | - | - | -77 | 6 | 30 |
| Net income 1 | - | - | -76.6 | 6 | 30 |
| Net margin | - | - | -377.34% | 11.43% | 38.22% |
| EPS | - | - | - | - | - |
| Free Cash Flow 1 | -33.59 | -23.84 | -77 | -52 | -24 |
| FCF margin | -842.6% | -260.32% | -379.31% | -99.05% | -30.57% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/29/22 | 4/6/23 | - | - | - |
1PLN in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|
| Net sales 1 | - | - | 11.7 | 7 |
| EBITDA 1 | - | -15.05 | -12.8 | -13.5 |
| EBIT 1 | - | -16.27 | -15.7 | -15.4 |
| Operating Margin | - | - | -134.19% | -220% |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income 1 | -43.32 | -15.78 | -13 | -14.9 |
| Net margin | - | - | -111.11% | -212.86% |
| EPS | -10.29 | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 9/7/23 | 11/28/23 | - | - |
1PLN in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | 110 | 83.9 | 62.5 | 42.8 | 51.3 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | -33.6 | -23.8 | -77 | -52 | -24 |
| ROE (net income / shareholders' equity) | -52.9% | -32.6% | -86.6% | -98.9% | -90% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | 5.11 | 0.89 | 5 | 5.5 | 7.5 |
| Capex / Sales | 128.27% | 9.74% | 24.63% | 10.48% | 9.55% |
| Announcement Date | 4/29/22 | 4/6/23 | - | - | - |
1PLN in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
79.8
PLN
Average target price
115
PLN
Spread / Average Target
+44.11%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -19.39% | 91.58M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- CTX Stock
- Financials Captor Therapeutics Spolka Akcyjna
